DAXOR CORP 10-Q Summary: Period Ended June 30, 2001
Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 2001, for DAXOR Corporation. The company operates in the medical technology sector, specifically focusing on the Blood Volume Analyzer (BVA-100) and localized semen and blood banking services. The company is currently transitioning its sales strategy from direct sales to leasing and distribution networks to facilitate hospital testing of its equipment.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $1,327,214 | $1,357,779 |
| Operating Revenues | $278,994 | $361,997 |
| Dividend Income | $939,165 | $939,545 |
| Net Income (Loss) | $134,224 | $32,232 |
| Net Income Before Taxes | $157,816 | $33,592 |
| Total Assets | $48,207,158 | $49,575,118 |
| Total Liabilities | $10,538,927 | $10,903,280 |
| Shareholders' Equity | $37,668,231 | $38,671,838 |
| Cash and Cash Equivalents | $44,240 | $67,783 (Beginning of 2000) |
| Net Cash from Operating Activities | $144,555 | $122,556 |
Debt and Liquidity: The company holds short-term loans of $1,985,679, consisting of a $1,000,000 bank loan secured by marketable securities and $985,679 in margin debt due to brokers. The portfolio of marketable securities has a fair value of $47,271,440, representing the vast majority of total assets.
Material Changes vs. Prior Period
- Revenue Composition: While total revenues decreased slightly by 2.2% year-over-year, operating revenues declined significantly by 22.9% ($278,994 vs. $361,997). This decline is attributed to a strategic shift from direct sales of the BVA-100 to a leasing model, which delays revenue recognition.
- Profitability: Net income increased substantially to $134,224 from $32,232 in the prior year. This improvement was driven by a reduction in operating expenses (Laboratory operations and SG&A) and lower net interest expense ($69,583 vs. $100,174), despite the drop in operating revenue.
- Investment Portfolio: The unrealized holding gain on available-for-sale securities decreased from $27,425,484 at year-end 2000 to $25,524,380 at June 30, 2001, reflecting market fluctuations in the equity portfolio.
Outlook, Risks, and Management Commentary
Management anticipates that sales of equipment and kits will become the primary income source. The company is actively negotiating a distribution agreement for the Blood Volume Analyzer in Japan and evaluating options for a nationwide sales force versus independent dealer networks. A key operational risk is the "instrument loaner reagent plan," which allows users minimal initial capital commitment but results in a slower return on capital expenditure for DAXOR. The company is considering selling equipment to independent leasing companies to mitigate this. There are no reported legal proceedings.
Investor Verification Checklist
- Revenue Recognition Policy: Verify the impact of the shift from direct sales to leasing on future revenue recognition timelines and cash flow stability.
- Portfolio Concentration: Assess the risk associated with Total Assets being 98% comprised of marketable securities ($47.3M of $48.2M).
- Debt Covenants: Review the terms of the $1.98M in secured loans and margin debt to understand potential liquidation risks if the securities portfolio value declines.
- International Expansion: Monitor the status of the pending distribution agreement in Japan as a potential growth catalyst.
- Operating Cash Flow: Confirm that operating cash flow remains sufficient to cover interest expenses and operational costs without relying on the sale of securities.